Table 2.
COVID-19 MS patients clinical features, SARS-CoV-2 serology, IgM and IgG antibody titers
| Sex | Age (years) | EDSS | Disease type | Current DMT | DMT duration (months) | Duration between last anti-CD20 administration and symptom onset (days) | SARS-CoV-2 severity | Duration between SARS-CoV-2 clinical onset and SARS-CoV-2 serology (days) | SARS-CoV-2 serology IgG index/positivity | SARS-CoV-2 serology IgM index/positivity |
|---|---|---|---|---|---|---|---|---|---|---|
| F | 41 | 1.5 | RRMS | GA | 39 | – | Mild | 107 | 0.26/– | 0.38/– |
| F | 40 | 1 | RRMS | GA | 119 | – | Mild | 135 | 0.50/– | 0.41/– |
| F | 42 | 1 | RRMS | INF-β | 98 | – | Mild | 40 | 2.53/+ | 5.99/+ |
| F | 32 | 1 | RRMS | Trf | 72 | – | Mild | 25 | 0.88/– | 1.56/+ |
| M | 49 | 1 | RRMS | Trf | 6 | – | Mild | 14 | 3.97/+ | 8.28/+ |
| F | 50 | 2 | RRMS | Trf | 76 | – | Mild | 158 | 5.01/+ | 3.89/+ |
| F | 25 | 1 | RRMS | DMF | 15 | – | Mild | 89 | 1.15/+ | 0.13/– |
| F | 34 | 2 | RRMS | DMF | 48 | – | Mild | 128 | 0.46/– | 0.31/– |
| F | 41 | 2 | RRMS | Fing | 20 | – | Severe | 32 | 5.57/+ | 10.31/+ |
| F | 40 | 3 | RRMS | Fing | 23 | – | Moderate | 65 | 3.43/+ | 3.47/+ |
| F | 23 | 3 | RRMS | Ntz | 15 | – | Mild | 59 | 7.07/+ | 4.51/+ |
| M | 51 | 4.5 | SPMS | Ocre | 10 | 52 | Severe | 30 | 11.14/+ | 9.38/+ |
| F | 39 | 4 | SPMS | Ocre | 29 | 60 | Mild | 58 | 0.00/– | 0.04/– |
| M | 42 | 3 | SPMS | Ocre | 12 | 45 | Moderate | 102 | 2.74/+ | 3.98/+ |
| M | 39 | 3.5 | SPMS | Ocre | 31 | 150 | Moderate | 130 | 0.06/– | 0/– |
| M | 34 | 4 | SPMS | Rtx | 34 | 88 | Mild | 160 | 0.11/– | 0/– |
| M | 38 | 3.5 | SPMS | Rtx | 39 | 300 | Mild | 22 | 0.20/– | 0.35/– |
F female, M Male, DMT disease-modifying therapy, RRMS relapsing remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, GA glatiramer acetate, INF-β interferon-β, Trf teriflunamide, DMF dimethyl fumarate, Fing fingolimod, Ntz natalizumab, Ocre ocrelizumab, Rtx rituximab